- Home
- LFMDP vs HUMAW Comparison
LFMDP vs HUMAW Comparison
Compare LFMDP & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFMDP
- HUMAW
- Stock Information
- Founded
- LFMDP N/A
- HUMAW 2004
- Country
- LFMDP United States
- HUMAW United States
- Employees
- LFMDP 336
- HUMAW 220
- Industry
- LFMDP Medical/Nursing Services
- HUMAW Biotechnology: Pharmaceutical Preparations
- Sector
- LFMDP Health Care
- HUMAW Health Care
- Exchange
- LFMDP Nasdaq
- HUMAW Nasdaq
- Market Cap
- LFMDP N/A
- HUMAW N/A
- IPO Year
- LFMDP N/A
- HUMAW N/A
- Fundamental
- Price
- LFMDP $23.40
- HUMAW $0.27
- Analyst Decision
- LFMDP
- HUMAW
- Analyst Count
- LFMDP 0
- HUMAW 0
- Target Price
- LFMDP N/A
- HUMAW N/A
- AVG Volume (30 Days)
- LFMDP N/A
- HUMAW 14.2K
- Earning Date
- LFMDP N/A
- HUMAW 03-21-2025
- Dividend Yield
- LFMDP N/A
- HUMAW N/A
- EPS Growth
- LFMDP N/A
- HUMAW N/A
- EPS
- LFMDP N/A
- HUMAW N/A
- Revenue
- LFMDP N/A
- HUMAW N/A
- Revenue This Year
- LFMDP N/A
- HUMAW N/A
- Revenue Next Year
- LFMDP N/A
- HUMAW N/A
- P/E Ratio
- LFMDP N/A
- HUMAW N/A
- Revenue Growth
- LFMDP N/A
- HUMAW N/A
- 52 Week Low
- LFMDP N/A
- HUMAW $1.18
- 52 Week High
- LFMDP N/A
- HUMAW $1.34
- Technical
- Relative Strength Index (RSI)
- LFMDP 43.39
- HUMAW N/A
- Support Level
- LFMDP $23.05
- HUMAW N/A
- Resistance Level
- LFMDP $24.25
- HUMAW N/A
- Average True Range (ATR)
- LFMDP 0.27
- HUMAW 0.00
- MACD
- LFMDP -0.09
- HUMAW 0.00
- Stochastic Oscillator
- LFMDP 27.13
- HUMAW 0.00
About LFMDP LifeMD Inc.
LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.
About HUMAW Humacyte Inc. Warrant
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.